Palisade Bio (PALI) FCF Margin (2011 - 2026)

Palisade Bio (PALI) posted quarterly FCF Margin of 1410.4% for Q1 2023, up 97.72% quarter-over-quarter from 61960.0% in Q4 2020.

Palisade Bio (PALI) FCF Margin (2011 - 2026) Analysis & Trends

Palisade Bio (PALI) has reported FCF Margin for 11 consecutive years, with 1410.4% the latest figure, recorded in Q1 2023.

In Q1 2023, FCF Margin changed N/A year-over-year to 1410.4%; the TTM figure through Dec 2023 stood at 4453.2% (changed N/A YoY), while the FY2023 annual figure was 4454.8%, changed N/A from the prior year.
FCF Margin climbed to 1410.4% in Q1 2023 per PALI's latest filing, from 61960.0% in the prior quarter.
Across five years, FCF Margin topped out at 1410.4% in Q1 2023 and bottomed at 81957.28% in Q4 2019.
Historically, FCF Margin has averaged 44127.59% across 3 years, with a median of 34720.0% in 2020.
Annual changes were most pronounced in 2019 — FCF Margin sank 1953800 bps — and 2020, when it surged 4116960 bps.
Palisade Bio's FCF Margin stood at 81957.28% in 2019, then rose by 24 bps to 61960.0% in 2020, then surged by 98 bps to 1410.4% in 2023.
Business Quant data shows PALI's FCF Margin at 1410.4% in Q1 2023, 61960.0% in Q4 2020, and 34720.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-1,520.60%

Download Data